A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 4, 2010, Pages 445-451

  Voora, D ^a,b   Koboldt, D C ^c   King, C R ^a   Lenzini, P A ^a   Eby, C S ^a   Porche Sorbet, R ^a   Deych, E ^a   Crankshaw, M ^c   Milligan, P E ^a   McLeod, H L ^a   Patel, S R ^d   Cavallari, L H ^d   Ridker, P M ^e   Grice, G R ^a   Miller, R D ^c   Gage, B F ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CALUMENIN; CYTOCHROME P450 2C9; MENADIONE EPOXIDE; SIMVASTATIN; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; ETHNICITY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VENOUS THROMBOEMBOLISM;

ADULT; AFRICAN AMERICANS; AGED; ALLELES; ANTICOAGULANTS; CALCIUM-BINDING PROTEINS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN;

EID: 77949874684     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.291     Document Type: Article

References (41)

1. Odén, A., Fahlén, M. & Hart, R.G. Optimal INR for prevention of stroke and death in atrial fbrillation: a critical appraisal. Thromb. Res. 117, 493-499 (2006).
2. Rieder, M.J. et al. Efect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
3. Caldwell, M.D. et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106-4112 (2008).
4. Limdi, N.A. et al. Infuence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9, 511-526 (2008).
5. Cooper, G.M. et al. A genome-wide scan for common genetic variants with a large infuence on warfarin maintenance dose. Blood 112, 1022-1027 (2008).
6. Takeuchi, F. et al. A genome-wide association study confrms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5, e1000433 (2009).
7. Teichert, M. et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum. Mol. Genet. 18, 3758-3768 (2009).
8. Schelleman, H. et al. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin. Pharmacol. Ther. 81, 742-747 (2007).
9. Gage, B.F. et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84, 326-331 (2008).
10. Diab, F. & Fefer, S. Hereditary warfarin resistance. South. Med. J. 87, 407-409 (1994).
11. Wallin, R., Hutson, S.M., Cain, D., Sweatt, A. & Sane, D.C. A molecular mechanism for genetic warfarin resistance in the rat. FASEB J. 15, 2542-2544 (2001).
12. Wajih, N., Sane, D.C., Hutson, S.M. & Wallin, R. The inhibitory efect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats. J. Biol. Chem. 279, 25276-25283 (2004).
13. Wajih, N., Hutson, S.M. & Wallin, R. siRNA silencing of calumenin enhances functional factor IX production. Blood 108, 3757-3760 (2006).
14. Vecsler, M. et al. Combined genetic profles of components and regulators of the vitamin K-dependent gamma-carboxylation system afect individual sensitivity to warfarin. Thromb. Haemost. 95, 205-211 (2006).
15. Kimura, R. et al. Polymorphisms in vitamin K-dependent gamma-carboxylation-related genes infuence interindividual variability in plasma protein C and protein S activities in the general population. Int. J. Hematol. 84, 387-397 (2006).
16. Wadelius, M. et al. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121, 23-34 (2007).
17. Satagopan, J.M., Venkatraman, E.S. & Begg, C.B. Two-stage designs for gene-disease association studies with sample size constraints. Biometrics 60, 589-597 (2004).
18. Cohen, J.C., Kiss, R.S., Pertsemlidis, A., Marcel, Y.L., McPherson, R. & Hobbs, H.H. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305, 869-872 (2004).
19. Cohen, J., Pertsemlidis, A., Kotowski, I.K., Graham, R., Garcia, C.K. & Hobbs, H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161-165 (2005).
20. Arking, D.E. et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat. Genet. 38, 644-651 (2006).
21. González-Conejero, R. et al. The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. J. Thromb. Haemost. 5, 1701-1706 (2007).
22. Wadelius, M. et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113, 784-792 (2009).
23. Thacker, S.M., Grice, G.R., Milligan, P.E. & Gage, B.F. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes. J. Thromb. Haemost. 6, 1445-1449 (2008).
24. Vorum, H., Liu, X., Madsen, P., Rasmussen, H.H. & Honoré, B. Molecular cloning of a cDNA encoding human calumenin, expression in Escherichia coli and analysis of its Ca2+-binding activity. Biochim. Biophys. Acta 1386, 121-131 (1998).
25. Presnell, S.R. & Staford, D.W. The vitamin K-dependent carboxylase. Thromb. Haemost. 87, 937-946 (2002).
26. Rost, S. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor defciency type 2. Nature 427, 537-541 (2004).
27. Wajih, N., Owen, J. & Wallin, R. Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection. Thromb. Res. 122, 405-410 (2008).
28. Stranger, B.E. et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315, 848-853 (2007).
29. Barrett, J.C., Fry, B., Maller, J. & Daly, M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
30. Limdi, N.A. et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9, 1445-1458 (2008).
31. Lenzini, P.A. et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J. Thromb. Haemost. 6, 1655-1662 (2008).
32. Voora, D. et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb. Haemost. 93, 700-705 (2005).
33. Ridker, P.M. et al.; PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N. Engl. J. Med. 348, 1425-1434 (2003).
34. Momary, K.M., Shapiro, N.L., Viana, M.A., Nutescu, E.A., Helgason, C.M. & Cavallari, L.H. Factors infuencing warfarin dose requirements in African-Americans. Pharmacogenomics 8, 1535-1544 (2007).
35. Ge, D. et al. WGAViewer: software for genomic annotation of whole genome association studies. Genome Res. 18, 640-643 (2008).
36. Stranger, B.E. et al. Population genomics of human gene expression. Nat. Genet. 39, 1217-1224 (2007).
37. Miller, R.D., Duan, S., Lovins, E.G., Kloss, E.F. & Kwok, P.Y. Efcient high-throughput resequencing of genomic DNA. Genome Res. 13, 717-720 (2003).
38. Marsh, S., King, C.R., Garsa, A.A. & McLeod, H.L. Pyrosequencing of clinically relevant polymorphisms. Methods Mol. Biol. 311, 97-114 (2005).
39. King, C.R. & Scott-Horton, T. Pyrosequencing: a simple method for accurate genotyping. Methods Mol. Biol. 373, 39-56 (2007).
40. Ronaghi, M., Uhlén, M. & Nyrén, P. A sequencing method based on real-time pyrophosphate. Science 281, 363, 365 (1998).
41. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B. 57, 289-300 (1995).